Document:

<PAGE>
                                                                   EXHIBIT 10.16

                               EXECUTIVE AGREEMENT

         This Executive Agreement ("Agreement") between Oil States
International, Inc., a Delaware corporation (the "Company"), and Sandy Slator
(the "Executive") is made and entered into effective as of the date of the
consummation of the initial public offering of the common stock of the Company
(the "Effective Date").

         WHEREAS, Executive is a key executive of the Company or a subsidiary;
and

         WHEREAS, the Company believes it to be in the best interests of its
stockholders to attract, retain and motivate key executives and ensure
continuity of management; and

         WHEREAS, it is in the best interest of the Company and its stockholders
if the key executives can approach material business development decisions
objectively and without concern for their personal situation; and

         WHEREAS, the Company recognizes that the possibility of a Change of
Control (as defined below) of the Company may result in the departure of key
executives to the detriment of the Company and its stockholders; and

         WHEREAS, the Board of Directors of the Company has authorized this
Agreement and certain similar agreements in order to retain and motivate key
management and to ensure continuity of key management;

         THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Company and Executive agree as
follows:

1.       TERM OF AGREEMENT

         A.       This Agreement shall commence on the Effective Date and,
                  subject to the provisions for earlier termination in this
                  Agreement, shall continue in effect through the third
                  anniversary of the Effective Date; provided, however,
                  commencing on the Effective Date and on each day thereafter,
                  the term of this Agreement shall automatically be extended for
                  one additional day unless the Board of Directors of the
                  Company shall give written notice to Executive that the term
                  shall cease to be so extended in which event the Agreement
                  shall terminate on the third anniversary of the date such
                  notice is given.

         B.       Notwithstanding anything in this Agreement to the contrary,
                  this Agreement, if in effect on the date of a Change of
                  Control, shall automatically be extended for the 24-month
                  period following the Change of Control.

         C.       Termination of this Agreement shall not alter or impair any
                  rights of Executive arising hereunder on or before such
                  termination.

<PAGE>
7
2.       CERTAIN DEFINITIONS

         A.       "Cause" shall mean:

                  (i)      Executive's conviction of (or plea of nolo contendere
                           to) a felony, dishonesty or a breach of trust as
                           regards the Company or any subsidiary;

                  (ii)     Executive's commission of any act of theft, fraud,
                           embezzlement or misappropriation against the Company
                           or any subsidiary that is materially injurious to the
                           Company or such subsidiary regardless of whether a
                           criminal conviction is obtained;

                  (iii)    Executive's willful and continued failure to devote
                           substantially all of his business time to the
                           Company's business affairs (excluding failures due to
                           illness, incapacity, vacations, incidental civic
                           activities and incidental personal time) which
                           failure is not remedied within a reasonable time
                           after written demand is delivered by the Company,
                           which demand specifically identifies the manner in
                           which the Company believes that Executive has failed
                           to devote substantially all of his business time to
                           the Company's business affairs; or

                  (iv)     Executive's unauthorized disclosure of confidential
                           information of the Company that is materially
                           injurious to the Company.

                           For purposes of this definition, no act, or failure
                  to act, on Executive's part shall be deemed "willful" unless
                  done, or omitted to be done, by Executive not in good faith
                  and without reasonable belief that Executive's action or
                  omission was in the best interest of the Company.

         B.       "Change of Control" shall mean any of the following:

                  (i)      any "person" (as such term is used in Section 13(d)
                           and 14(d) of the Securities Exchange Act of 1934, as
                           amended (the "Exchange Act")), (other than a trustee
                           or other fiduciary holding securities under an
                           employee benefit plan of the Company or any
                           affiliate, SCF III, L.P., SCF IV, L.P., or any
                           affiliate of SCF-III, L.P. or SCF-IV, L.P. or any
                           corporation owned, directly or indirectly, by the
                           stockholders of the Company in substantially the same
                           proportions as their ownership of stock of the
                           Company), acquires "beneficial ownership" (within the
                           meaning of Rule 13d-3 under the Exchange Act) of
                           securities of the Company representing 35% or more of
                           the combined voting power of the Company's then
                           outstanding securities; provided, however, that if
                           the Company engages in a merger or consolidation in
                           which the Company or surviving entity in such merger
                           or consolidation becomes a subsidiary of another
                           entity, then references to the Company's then
                           outstanding securities shall be deemed to refer to
                           the outstanding securities of such parent entity;

                                       2
<PAGE>

                  (ii)     a change in the composition of the Board, as a result
                           of which fewer than a majority of the directors are
                           Incumbent Directors. "Incumbent Directors" shall mean
                           directors who either (i) are directors of the Company
                           as of the Effective Date, or (ii) are elected, or
                           nominated for election, to the Board with the
                           affirmative votes of at least two-thirds of the
                           Incumbent Directors at the time of such election or
                           nomination, but Incumbent Director shall not include
                           an individual whose election or nomination occurs as
                           a result of either (1) an actual or threatened
                           election contest (as such terms are used in Rule
                           14a-11 of Regulation 14A promulgated under the
                           Exchange Act) or (2) an actual or threatened
                           solicitation of proxies or consents by or on behalf
                           of a person other than the Board of Directors of the
                           Company;

                  (iii)    the consummation of a merger or consolidation of the
                           Company with any other corporation, other than a
                           merger or consolidation which would result in the
                           voting securities of the Company outstanding
                           immediately prior thereto continuing to represent
                           (either by remaining outstanding or by being
                           converted into voting securities of the surviving
                           entity (or if the surviving entity is or shall become
                           a subsidiary of another entity, then such parent
                           entity)) more than 50% of the combined voting power
                           of the voting securities of the Company (or such
                           surviving entity or parent entity, as the case may
                           be) outstanding immediately after such merger or
                           consolidation;

                  (iv)     the stockholders of the Company approve a plan of
                           complete liquidation of the Company; or

                  (v)      the sale or disposition (other than a pledge or
                           similar encumbrance) by the Company of all or
                           substantially all of the assets of the Company other
                           than to a subsidiary or subsidiaries of the Company.

         C.       "Date of Termination" shall mean the date the Notice of
                  Termination is given unless such termination is by Executive
                  in which event the Date of Termination shall not be less than
                  30 days following the date the Notice of Termination is given.
                  Further, a Notice of Termination given by Executive due to a
                  Good Reason event that is corrected by the Company before the
                  Date of Termination shall be void.

         D.       "Good Reason" shall mean:

                  (i)      a material reduction in Executive's authority, duties
                           or responsibilities from those in effect immediately
                           prior to the Change of Control or the assignment to
                           Executive duties or responsibilities inconsistent in
                           any material respect from those of Executive in
                           effect immediately prior to the Change of Control;

                  (ii)     a material reduction of Executive's compensation and
                           benefits, including, without limitation, annual base
                           salary, annual bonus, and equity incentive

                                       3
<PAGE>

                           opportunities, from those in effect immediately prior
                           to the Change of Control;

                  (iii)    the Company fails to obtain a written agreement from
                           any successor or assigns of the Company to assume and
                           perform this Agreement as provided in Section 9
                           hereof; or

                  (iv)     the Company requires Executive, without Executive's
                           consent, to be based at any office located more than
                           50 miles from the Company's offices to which
                           Executive was based immediately prior to the Change
                           of Control, except for travel reasonably required in
                           the performance of Executive's duties.

                  Notwithstanding the above however, Good Reason shall not exist
                  with respect to a matter unless Executive gives the Company
                  written notice of such matter within 30 days of the date
                  Executive knows or should reasonably have known of its
                  occurrence. If Executive fails to give such notice timely,
                  Executive shall be deemed to have waived all rights Executive
                  may have under this Agreement with respect to such matter.

         E.       "Notice of Termination" shall mean a written notice delivered
                  to the other party indicating the specific termination
                  provision in this Agreement relied upon for termination of
                  Executive's employment and shall set forth in reasonable
                  detail the facts and circumstances claimed to provide a basis
                  for termination of Executive's employment under the provision
                  so indicated.

         F.       "Protected Period" shall mean the 24-month period beginning on
                  the effective date of a Change of Control.

         G.       "Target AICP" shall mean the targeted value of Executive's
                  annual incentive compensation plan bonus for the year in which
                  the Date of Termination occurs or the fiscal year immediately
                  preceding the Change of Control, whichever is a greater
                  amount.

         H.       "Termination Base Salary" shall mean Executive's base salary
                  at the rate in effect at the time the Notice of Termination is
                  given or, if a greater amount, Executive's base salary at the
                  rate in effect immediately prior to the Change of Control.

3.       NO EMPLOYMENT AGREEMENT.

         This Agreement shall be considered solely as a "severance agreement"
         obligating the Company to pay Executive certain amounts of compensation
         and to provide certain benefits in the event and only in the event of
         Executive's termination of employment for the specified reasons and at
         the times specified herein. The parties agree that this Agreement shall
         not be considered an employment agreement and that Executive is an "at
         will" employee of the Company.

                                       4
<PAGE>

4.       REGULAR SEVERANCE BENEFITS.

         Subject to Section 13, if the Company terminates Executive's employment
         (i) other than for Cause and (ii) not during the Protected Period,
         Executive shall receive the following compensation and benefits from
         the Company:

         A.       Within 15 days of the Date of Termination the Company shall
                  pay to Executive in a lump sum, in cash, an amount equal to
                  one times the sum of Executive's (i) Termination Base Salary
                  and (ii) Target AICP.

         B.       Notwithstanding anything in any Company stock plan or grant
                  agreement to the contrary, all restricted shares and
                  restricted stock units of Executive shall become 100% vested
                  and all restrictions thereon shall lapse as of the Date of
                  Termination and the Company shall promptly deliver such shares
                  to Executive.

         C.       For the 24-month period following the Date of Termination (the
                  "Regular Severance Period"), the Company shall continue to
                  provide Executive and Executive's eligible family members,
                  based on the cost sharing arrangement between the Company and
                  similarly situated active employees, with medical and dental
                  health benefits and disability coverage and benefits at least
                  equal to those which would have been provided to Executive if
                  Executive's employment had not been terminated or, if more
                  favorable to Executive, as in effect generally at any time
                  during such period. Notwithstanding the foregoing, if
                  Executive becomes eligible to receive medical, dental and
                  disability benefits under another employer's plans during this
                  Regular Severance Period, the Company's obligations under this
                  Section 4C shall be reduced to the extent comparable benefits
                  are actually received by Executive during such period, and any
                  such benefits actually received by Executive shall be promptly
                  reported by Executive to the Company. In the event Executive
                  is ineligible under the terms of the Company's health and
                  other welfare benefit plans or programs to continue to be so
                  covered, the Company shall provide Executive with
                  substantially equivalent coverage through other sources or
                  will provide Executive with a lump sum payment in such amount
                  that, after all taxes on that amount, shall be equal to the
                  cost to Executive of providing Executive such benefit
                  coverage. The lump sum shall be determined on a present value
                  basis using the interest rate provided in Section
                  1274(b)(2)(B) of the Internal Revenue Code of 1986, as amended
                  (the "Code") on the Date of Termination.

CHANGE OF CONTROL SEVERANCE BENEFITS

5.       SEVERANCE BENEFITS. Subject to Section 13, if either (a) Executive
         terminates his employment during the Protected Period for a Good Reason
         event or (b) the Company terminates Executive's employment during the
         Protected Period other than for Cause, Executive shall receive the
         following compensation and benefits from the Company:

                                       5
<PAGE>

         A.       Within 15 days of the Date of Termination the Company shall
                  pay to Executive in a lump sum, in cash, an amount equal to
                  two times the sum of Executive's (i) Termination Base Salary
                  and (ii) Target AICP.

         B.       Notwithstanding anything in any Company stock plan or grant
                  agreement to the contrary, (i) all restricted shares and
                  restricted stock units of Executive shall become 100% vested
                  and all restrictions thereon shall lapse as of the Date of
                  Termination and the Company shall promptly deliver such shares
                  to Executive and (ii) each then outstanding stock option of
                  Executive shall become 100% exercisable and, excluding any
                  incentive stock option granted prior to the Effective Date,
                  shall remain exercisable for the remainder of such option's
                  term.

         C.       Executive shall be fully vested in Executive's accrued
                  benefits under all qualified pension, nonqualified pension,
                  profit sharing, 401(k), deferred compensation and supplemental
                  plans maintained by the Company for Executive's benefit,
                  except to that the extent the acceleration of vesting of such
                  benefits would violate any applicable law or require the
                  Company to accelerate the vesting of the accrued benefits of
                  all participants in such plan or plans, in which event the
                  Company shall pay Executive a lump sum amount, in cash, within
                  15 days following the Date of Termination, equal to the
                  present value of such unvested accrued benefits that cannot
                  become vested under the plan for the reasons provided above.

         D.       For the 36-month period following the Date of Termination (the
                  "COC Severance Period"), the Company shall continue to provide
                  Executive and Executive's eligible family members, based on
                  the cost sharing arrangement between Executive and the Company
                  on the Date of Termination, with medical and dental health
                  benefits and disability coverage and benefits at least equal
                  to those which would have been provided to Executive if
                  Executive's employment had not been terminated or, if more
                  favorable to Executive, as in effect generally at any time
                  during such period. Notwithstanding the foregoing, if
                  Executive becomes eligible to receive medical, dental and
                  disability benefits under another employer's plans during this
                  COC Severance Period, the Company's obligations under this
                  Section 5D shall be reduced to the extent comparable benefits
                  are actually received by Executive during such period, and any
                  such benefits actually received by Executive shall be promptly
                  reported by Executive to the Company. In the event Executive
                  is ineligible under the terms of the Company's health and
                  other welfare benefit plans or programs to continue to be so
                  covered, the Company shall provide Executive with
                  substantially equivalent coverage through other sources or
                  will provide Executive with a lump sum payment in such amount
                  that, after all taxes on that amount, shall be equal to the
                  cost to Executive of providing Executive such benefit
                  coverage. The lump sum shall be determined on a present value
                  basis using the interest rate provided in Section
                  1274(b)(2)(B) of the Code on the Date of Termination.

         E.       Throughout the term of the COC Severance Period or until
                  Executive accepts other employment, including as an
                  independent contractor, with a new employer, whichever occurs
                  first, Executive shall be entitled to receive outplacement

                                       6
<PAGE>

                  services, payable by the Company, with an aggregate cost not
                  to exceed 15% of Executive's Termination Base Salary, with an
                  executive outplacement service firm reasonably acceptable to
                  the Company and Executive.

6.       PARACHUTE TAX GROSS UP.

         If any payment (including without limitation any imputed income) made,
         or benefit provided, to or on behalf of Executive pursuant to this
         Agreement, including any accelerated vesting or any deferred
         compensation or other award, in connection with a "change in control"
         of the Company (within the meaning of Section 280G of the Code) results
         in Executive being subject to the excise tax imposed by Section 4999 of
         the Code (or any successor or similar provision) the Company shall
         promptly pay Executive an additional amount in cash (the "Additional
         Amount") such that the net amount of all such payments and benefits
         received by Executive after paying all applicable taxes (including
         penalties and interest) on such payments and benefits, including on
         such Additional Amount, shall be equal to the net after-tax amount of
         the payments and benefits (excluding the Additional Amount) that
         Executive would have received if Section 4999 were not applicable to
         such payments and benefits. Such determinations shall be made by the
         Company's independent certified public accountants.

7.       ACCELERATED VESTING OF OPTIONS UPON A CHANGE OF CONTROL.

         Notwithstanding any provisions of any Company stock option plan or
         option agreement to the contrary, upon a Change of Control all
         outstanding unvested stock options, if any, granted to Executive under
         any Company stock option plan (or options substituted therefor covering
         the stock of a successor corporation) shall be fully vested and
         exercisable as to all shares of stock covered thereby effective as of
         the date of the Change of Control.

8.       MITIGATION.

         Executive shall not be required to mitigate the amount of any payment
         provided for in this Agreement by seeking other employment or otherwise
         nor, except as provided in Section 4C and Section 5D, shall the amount
         of any payment or benefit provided for in this Agreement be reduced by
         any compensation earned or benefit received by Executive as the result
         of employment by another employer or self-employment, by retirement
         benefits, by offset against any amount claimed to be owed by Executive
         to the Company or otherwise, except that any severance payments or
         benefits that Executive is entitled to receive pursuant to a Company
         severance plan or program for employees in general shall reduce the
         amount of payments and benefits otherwise payable or to be provided
         under this Agreement.

9.       SUCCESSOR AGREEMENT.

         The Company will require any successor (whether direct or indirect, by
         purchase, merger, consolidation or otherwise) to all or substantially
         all of the business and/or assets of the Company to assume expressly
         and agree to perform this Agreement in the same manner and to the same
         extent that the Company would be required to perform if no succession

                                       7
<PAGE>

         had taken place. Failure of the successor to so assume shall constitute
         a breach of this Agreement and entitle Executive to the benefits
         hereunder as if triggered by a termination by the Company other than
         for Cause.

10.      INDEMNITY.

         In any situation where under applicable law the Company has the power
         to indemnify, advance expenses to and defend Executive in respect of
         any judgements, fines, settlements, loss, cost or expense (including
         attorneys fees) of any nature related to or arising out of Executive's
         activities as an agent, employee, officer or director of the Company or
         in any other capacity on behalf of or at the request of the Company,
         then the Company shall promptly on written request, indemnify
         Executive, advance expenses (including attorney's fees) to Executive
         and defend Executive to the fullest extent permitted by applicable law,
         including but not limited to making such findings and determinations
         and taking any and all such actions as the Company may, under
         applicable law, be permitted to have the discretion to take so as to
         effectuate such indemnification, advancement or defense. Such agreement
         by the Company shall not be deemed to impair any other obligation of
         the Company respecting Executive's indemnification or defense otherwise
         arising out of this or any other agreement or promise of the Company
         under any statute.

11.      NOTICE.

         For the purpose of this Agreement, notices and all other communications
         provided for in this Agreement shall be in writing and delivered by
         United States certified or registered mail (return receipt requested,
         postage prepaid) or by courier guaranteeing overnight delivery or by
         hand delivery (with signed receipt required), addressed to the
         respective addresses set forth below, and such notice or communication
         shall be deemed to have been duly given two days after deposit in the
         mail, one day after deposit with such overnight carrier or upon
         delivery with hand delivery. The addresses set forth below may be
         changed by a writing in accordance herewith.

         Company:                                    Executive:

         Oil States International, Inc.              Sandy Slator
         333 Clay Street, Suite 3460                 10264 Connaught Drive
         Houston, Texas 77002                        Edmonton, Alberta T5N 3J2
         Attn: Chairman of the Board

12.      ARBITRATION.

         The parties agree to resolve any claim or controversy arising out of or
         relating to this Agreement, including but not limited to the
         termination of employment of Executive, by binding arbitration under
         the Federal Arbitration Act before one arbitrator in Houston, Texas,
         administered by the American Arbitration Association under its
         Commercial Arbitration Rules, and judgment on the award rendered by the
         arbitrator may be entered in any court having jurisdiction thereof. The
         fees and expenses of the arbitrator shall be borne solely by the
         non-prevailing party or, in the event there is no clear prevailing
         party,

                                       8
<PAGE>

         as the arbitrator deems appropriate. Except as provided above, each
         party shall pay its own costs and expenses (including, without
         limitation, attorneys' fees) relating to any mediation/arbitration
         proceeding conducted under this Section 12.

13.      WAIVER AND RELEASE.

         As a condition to the receipt of any payment or benefit under this
         Agreement, Executive must first execute and deliver to the Company a
         binding general release, as prepared by the Company, that releases the
         Company, its officers, directors, employees, agents, subsidiaries and
         affiliates from any and all claims and from any and all causes of
         action of any kind or character that Executive may have arising out of
         Executive's employment with the Company or the termination of such
         employment, but excluding (i) any claims and causes of action that
         Executive may have arising under or based upon this Agreement, and (ii)
         any vested rights Executive may have under any employee benefit plan or
         deferred compensation plan or program of the Company.

14.      EMPLOYMENT WITH AFFILIATES.

         Employment with the Company for purposes of this Agreement includes
         employment with any entity in which the Company has a direct or
         indirect ownership interest of 50% or more of the total combined voting
         power of all outstanding equity interests, and employment with any
         entity which has a direct or indirect interest of 50% or more of the
         total combined voting power of all outstanding equity interests of the
         Company. For purposes of this Agreement, "Good Reason" shall be
         construed to refer to Executive's positions, duties, and
         responsibilities in the position or positions in which Executive serves
         immediately before the Change of Control, but shall not include titles
         or positions with subsidiaries and affiliates of the Company that are
         held primarily for administrative convenience.

15.      GOVERNING LAW.

         (a)      THIS AGREEMENT WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE
                  WITH THE LAWS OF THE STATE OF TEXAS WITHOUT REGARD TO
                  CONFLICTS OF LAW PRINCIPLES.

         (b)      EACH PARTY HERETO HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE
                  JURISDICTION OF THE STATE AND FEDERAL COURTS IN HARRIS COUNTY,
                  TEXAS, FOR THE PURPOSES OF ANY PROCEEDING ARISING OUT OF THIS
                  AGREEMENT.

16.      ENTIRE AGREEMENT.

         This Agreement is an integration of the parties' agreement and no
         agreement or representatives, oral or otherwise, express or implied,
         with respect to the subject matter hereof have been made by either
         party which are not set forth expressly in this Agreement. This
         Agreement hereby expressly terminates, rescinds and replaces in full
         any prior agreement (written or oral) between the parties relating to
         the subject matter hereof.

                                       9
<PAGE>

17.      WITHHOLDING OF TAXES.

         The Company shall withhold from all payments and benefits provided
         under this Agreement all taxes required to be withheld by applicable
         law.

18.      BENEFICIARY.

         In the event Executive dies before receiving the lump sum severance
         payment to which Executive was entitled hereunder, Executive's spouse
         or, if there is no spouse, the beneficiary designated by Executive
         under the Company-sponsored group term life insurance plan, shall
         receive such payment.

         IN WITNESS WHEREOF, the Company and Executive have executed this
Agreement effective for all purposes as of the Effective Date.

                                        OIL STATES INTERNATIONAL, INC.

                                        By:  /s/ CINDY B. TAYLOR
                                           ------------------------------------
                                        Name:    Cindy B. Taylor
                                             ----------------------------------
                                        Title:   Senior Vice President - CFO
                                               --------------------------------

                                        EXECUTIVE /s/ SANDY SLATOR
                                        ---------------------------------------

                                       10<PAGE>

                                                                 Exhibit 10.1(j)

                                    AGREEMENT
                                    ---------

         This Agreement is made by and between Roche Molecular Systems, Inc.
("RMS"), having an office at 1080 U.S. Highway 202, Branchburg, New Jersey
08876-1760 and Genica Pharmaceuticals Corporation ("Genica"), Worcester,
Massachusetts, hereafter collectively referred to as "The Parties".

                                   BACKGROUND
                                   ----------

         A. RMS has the right to grant immunities from suit under certain United
States Patents describing and claiming, inter alia, a gene amplification process
known as the polymerase chain reaction ("PCR") technology.

         B. Genica has attained substantial expertise in validating, documenting
and performing sophisticated diagnostic procedures.

         C. Genica desires to obtain an immunity from suit from RMS to practice
PCR Technology to perform human in vitro clinical laboratory services, and RMS
                                --------
is willing to grant such an immunity, on the terms and subject to the conditions
provided exclusively in this Agreement.

         NOW, THEREFORE, for and in consideration of the mutual covenants
contained herein, RMS and Genica agree as follows:

* Material omitted and filed separately with the Securities and Exchange
Commission pursuant to request for confidential treatment under Rule 406.

<PAGE>
                                      -2-

1.       Definitions
         -----------

         For the purpose of this Agreement, and solely for that purpose, the
terms set forth hereinafter shall be defined as follows:

         1.1. The term "Affiliate" of a designated party to this Agreement shall
mean:

            (a)   an organization of which fifty percent (50%) or more of the
                  voting stock is controlled or owned directly or indirectly by
                  either party to this Agreement;

            (b)   an organization which directly or indirectly owns or controls
                  fifty percent (50%) or more of the voting stock of either
                  party to this Agreement;

            (c)   an organization, the majority ownership of which is directly
                  or indirectly common to the majority ownership of either party
                  to this Agreement; and

            (d)   an organization under (a), (b), or (c) above in which the
                  amount of said ownership is less than fifty percent (50%) and
                  that amount is the maximum amount permitted pursuant to the
                  law governing the ownership of said organization.

<PAGE>
                                      -3-

It is understood and agreed, however, that the term "Affiliate" shall not
include Genentech Inc., a company located at 460 Point San Bruno Boulevard,
South San Francisco, California, U.S.A. ("Genentech").

         1.2. "Assay" shall mean an in vitro diagnostic procedure utilizing PCR
Technology to detect the presence, absence or quantity of a nucleic acid
sequence associated with a specific human disease or condition.

         1.3. "Diagnostic Product" shall mean an assemblage of reagents,
including but not limited to reagents packaged in the form of a kit, useful in
performing an Assay.

         1.4. "Effective Date" shall mean the date on which the last signatory
to this Agreement signs the Agreement.

         1.5. "Licensed Field" shall mean the field of human in vitro
diagnostics solely for the detection of genetic diseases, genetic
pre-disposition to disease, microorganisms associated with infectious diseases,
cancer, or for tissue transplant typing or Parentage.

         1.6. "Licensed Services" shall mean the performance of an Assay by
Genica to detect nucleic acid sequences associated with a human disease or
condition within the Licensed Field. Licensed Services include but are not
limited to, any combination of the steps of col-

<PAGE>

                                      -4-

lecting a sample for analysis, isolating nucleic acid sequences therein,
amplifying one or more desired sequences, analyzing the amplified material and
reporting the results.

         1.7. "Licensed Technology" shall mean the application of PCR
Technology, as that term is defined in Section 1.10, to perform Licensed
Services.

         1.8. "Net Service Revenues" shall mean gross invoice price for the
Licensed Services performed by Genica (or the fair market value for any
nonmonetary consideration which Genica agrees to receive in exchange for
Licensed Services), less the following deductions where they are factually
applicable and are not already reflected in the gross invoice price:

              (i)    discounts allowed and taken, in amounts customary in the
                     trade (which shall include the difference between the
                     dollar amount charged by Genica for a Licensed Service and
                     the Medicare and/or Medicaid Limits of Allowance and/or
                     reimbursement limitations of a Third Party insurance
                     program); and

              (ii)   sales and/or use taxes and/or duties imposed upon and with
                     specific reference to particular sales; and

<PAGE>
                                      -5-

              (iii)  actual bad debt, up to [ ]%* of gross invoice price for
                     Licensed Services, which bad debt Genica can prove and
                     document that it was reasonable and diligent in its efforts
                     to collect payment.

         No allowance or deduction shall be made for commissions or collections,
by whatever name known.

         It is hereby understood and agreed that, to the extent feasible, the
Licensed Services shall at all times be invoiced, listed and billed by Genica as
a separate item in Genica's invoices, bills and reports to customers. However,
in the event a Licensed Service is offered in combination with another non-PCR
diagnostic assay(s) or together with a nontesting service(s) (e.g., an
interpretive or consultive service) as part of a package (e.g., genetic
counseling) (this combination of a Licensed Service with a nontesting or
interpretive service is hereinafter referred to as a "Combination Service"),
then Net Service Revenues for purposes of determining royalties on a Licensed
Service which is part of a Combination Service shall be determined by
multiplying the gross invoice price, less applicable deductions, for the
Combination Service, by the appropriate fraction in Attachment I hereto. The
fraction specified in Attachment I for a particular Licensed Service shall be
mutually agreed to by The Parties as accurately reflecting the value contributed
by the Licensed Service to the overall value of the package of the Combination
Service as offered by Genica. Attachment I hereto may be modified at any time by
mutual consent of The Parties.

<PAGE>
                                      -6-

         The Net Service Revenues of the Licensed Services that are performed by
Genica for any person, firm or corporation controlling, controlled by, or under
common control with Genica, or enjoying a special course of dealing with Genica,
shall be determined by reference to the Net Service Revenues which would be
applicable under this Section in an arm's length transaction by Genica to a
Third Party other than such person, firm or corporation.

         1.9. "Parentage" shall mean analysis of human genetic material to
ascertain whether two or more individuals are biologically related, but
specifically excludes analysis of forensic evidence for a criminal proceeding.

         1.10. "PCR Technology" shall mean polymerase chain reaction technology
covered by United States Patent Nos. B1 4,683,195 and B1 4,683,202 and any
reissue or reexamination patents thereof.

         1.11. "Third Party" shall mean a party other than an Affiliate of The
Parties to this Agreement.

2.       Grant
         -----

         2.1. Upon the terms and subject to the conditions of this Agreement,
RMS hereby grants to Genica, and Genica hereby accepts from RMS, a
royalty-bearing, nonexclusive immunity from suit under PCR Technology solely to
use Licensed Technology to perform Li-

<PAGE>

                                      -7-

censed Services within the United States and its possessions and the
Commonwealth of Puerto Rico. The Parties understand and agree that no rights are
hereby granted, expressly or by implication, under U.S. Patent No. 4,965,188
(the `l88 patent). An immunity from suit under the `188 patent may be obtained
by purchase of RMS-manufactured polymerase or by contacting the Director of
Licensing, Roche Molecular Systems, Inc., 1145 Atlantic Avenue, Alameda, CA
94501 (510/865-5400).

         2.2. The Licensed Technology hereunder may be practiced solely for the
performance of Licensed Services and for no other purpose whatsoever, and no
other right, immunity or license is granted expressly, impliedly or by estoppel.

         2.3. Genica expressly agrees that this Agreement is intended to and
does supersede all prior agreements between Genica and the Cetus Corporation,
RMS' predecessor in interest, relating to PCR Technology, including specifically
the agreement dated November 13, 1990.

         2.4. Genica expressly acknowledges and agrees that the immunity from
suit pursuant to this Agreement is personal to Genica alone and Genica shall
have no right to sublicense, assign or otherwise transfer or share its rights
under the foregoing immunity from suit and further agrees that Licensed Services
will be performed, offered, marketed and sold only by Genica and Genica shall
not authorize any other party, including Affiliates, to practice the Li

<PAGE>

                                       -8-

censed Technology, nor shall it practice the Licensed Technology in conjunction
with any other party.

         2.5. For each Combination Service that Genica offers pursuant to this
immunity from suit, Genica agrees that it will notify RMS at least sixty (60)
days before it commercializes said Combination Service. The Parties shall then
agree on the fraction of the value of Combination Services which is attributable
to the Licensed Service component. As to all other Licensed Services offered by
Genica which are not part of a Combination Service, Genica agrees to keep RMS
informed about the availability from Genica of each such Service within a
reasonable time after Genica commences offering the Service.

         2.6. RMS hereby grants to Genica the right and Genica accepts and
agrees to credit RMS as the source of PCR Technology rights in Genica's
promotional materials and any other materials intended for distribution to Third
Parties as follows:

         "This test is performed pursuant to a license agreement with Roche
Molecular Systems, Inc."

3.       Acknowledgment and Agreement on Diagnostic Products
         ---------------------------------------------------

         3.1. Genica acknowledges and agrees that the immunity from suit granted
hereunder is for the performance of Licensed Services only and does not include
any right to make, have made, import, offer or sell any products, including
devices, PCR reagents, kits or

<PAGE>

                                      -9-

Diagnostic Products. Genica further acknowledges and agrees that RMS Affiliates
are in the business of providing clinical laboratory testing services and the
commercial sale of diagnostic testing systems and therefore may compete directly
with Genica's business.

4.       Royalties, Records and Reports
         ------------------------------

         4.1.     Royalties.  For the rights and privileges granted under this
                  ---------
Agreement, Genica shall pay to RMS earned royalties equal to [              ]%*
of Genica's Net Service Revenues for each Assay performed.

<PAGE>

                                      -10-

         4.2. Genica shall keep full, true and accurate books of account
containing all particulars which may be necessary for the purpose of showing the
amount payable to RMS by way of royalty or by way of any other provision under
this Agreement. Such books and the supporting data shall be open at all
reasonable times, for three (3) years following the end of the calendar year to
which they pertain (and access shall not be denied thereafter, if reasonably
available), to the inspection of RMS or an independent certified public
accountant retained by RMS for the purpose of verifying Genica's royalty
statements or Genica's compliance in other respects with this Agreement. If in
dispute, such records shall be kept until the dispute is settled. The inspection
of records shall be at RMS' sole cost and expense, unless the inspector
concludes that royalties reported by Genica for the period being audited are
understated by [ ]%* or more from actual royalties, in which case the costs and
expenses of such inspection shall be paid by Genica.

         4.3. Genica shall within thirty (30) days after the first day of
January, April, July and October of each year deliver to RMS a true and accurate
royalty report. This report shall give such particulars of the business
conducted by Genica during the preceding three (3) calendar months as are
pertinent to an accounting for royalty under this Agreement and shall include at
least the following:

<PAGE>
                                      -11-

                     (a)    the number of assays performed in connection with
                            performance of the Licensed Services and Combination
                            Services during those three (3) months;

                     (b)    compilation of billings thereon and the allowable
                            deductions therefrom;

                     (c)    Net Service Revenues and the calculation of total
                            royalties thereon; and

                     (d)    the calculation of the net royalty payable to RMS.
                            If no royalties are due it shall be so reported.

         The correctness and completeness of each such report shall be attested
to in writing by the responsible financial officer of Genica's organization or
by Genica's external auditor or by the chair or other head of Genica's internal
audit committee.

         Simultaneously with the delivery of each such report, Genica shall pay
to RMS the royalty and any other payments due under this Agreement for the
period covered by such report. All payments due RMS hereunder shall be sent
together with the royalty report by the due date to the following address:

                                     Roche Molecular Systems, Inc.
                                     P.O. Box 18139
                                     Newark, N.J. 07191

or to any address that RMS may advise in writing.

<PAGE>

                                      -12-

         4.4. All amounts payable hereunder by Genica to RMS shall be payable in
United States currency.

         4.5. Genica's obligation to pay royalties pursuant to this Agreement
shall terminate upon a final holding of invalidity or unenforceability of all of
the patents identified in Section 1.10, supra, by a court of appellate
                                        -----
jurisdiction or by a trial court from which no appeal is or can be taken.

         4.6. If Genica shall fail to pay any amount specified under this
Agreement after the due date thereof, the amount owed shall bear interest
[                 ]%* from the due date until paid, provided, however, that if
this interest rate is held to be unenforceable for any reason, the interest rate
shall be [                 ]* at the time the payment is due.

5.       Performance of Licensed Services
         --------------------------------

         5.1. The Parties agree that quality assurance is of utmost importance
in the performance of Licensed Services. To that end, Genica agrees that it
will:

              (a)    participate in at least one independent proficiency
                     testing program for each Licensed Service when such
                     program(s) becomes available; and

<PAGE>
                                      -13-

         (b)    comply with all Medicare, Medicaid and/or CLIA standards for
                diagnostic testing as well as all other applicable federal,
                state and local regulations applicable to human diagnostic
                testing.

6.       Technology Notification
         -----------------------

         6.1. With respect to any invention, improvement or discovery
(hereinafter referred to as "Discoveries" in this Article) of Genica made after
entering into this Agreement, resulting from work conducted under this Agreement
and being applicable to PCR, if Genica decides to license that Discovery to
Third Parties, then Genica agrees to provide to RMS, unless not possible due to
Genica's previous commitments to Third Parties relating to said Discoveries, a
reasonable opportunity to negotiate a license to use said Discoveries in
PCR-based diagnostic products and services. Such Discoveries include, but are
not limited to, improvements of the PCR process or in the performance of Assays,
modifications to or new methods of performing the Assays, including the
automation of the PCR process or of the Assays.

         6.2. Any agreement reached between The Parties as a result of Genica
notification to RMS of a Discovery pursuant to Section 6.1 hereto shall be upon
terms and conditions negotiated in good faith by The Parties.

<PAGE>

                                      -14-

7.       Diligence
         ---------

         Genica shall exercise reasonable diligence in developing, testing,
validating, documenting, promoting and selling the Licensed Services. In the
course of such diligence, Genica shall take appropriate steps including, upon
reasonable written request of RMS, furnishing RMS with representative copies of
all promotional material relating to the Licensed Services.

8.       Term and Termination
         --------------------

         8.1. The immunity from suit granted to Genica herein shall commence on
the Effective Date and terminate on the date of expiration of the last to expire
of the patents included within the PCR Technology, which patent contains at
least one claim covering the performance of Licensed Services.

         8.2. If in the course of performing and offering Licensed Services,
Genica fails to comply with the quality assurance provisions of Article 5,
Genica shall so notify RMS and RMS shall notify Genica to correct the defects.
Genica shall have thirty (30) days from receipt of such notice to cure all
defects of which it is notified. If Genica does not cure all such defects within
the designated thirty (30) days, RMS may then in its sole discretion terminate
this Agreement in its entirety, or any portion thereof immediately. For the
purposes of this Section and this Agreement, Genica's failure to provide an
accurate and correct test result when participating in an independent
proficiency testing program pursuant to Section 5.1 (a),

<PAGE>

                                      -15-

on two consecutive evaluations, shall automatically be deemed a failure to
comply with Article 5 and shall be a material breach of this Agreement.

         8.3. Notwithstanding any other Section of this Agreement, Genica may
terminate this Agreement for any reason on thirty (30) days' written notice to
RMS.

         8.4. The decision of a Court or Administrative body finding RMS liable
or culpable due to Genica's performance of Licensed Services shall give RMS the
right to terminate this Agreement immediately upon notification to RMS of said
decision.

         8.5. The immunity granted hereunder to Genica shall automatically
terminate upon (i) an adjudication of Genica as bankrupt or insolvent, or
Genica's admission in writing of its inability to pay its obligations as they
mature; or (ii) an assignment by Genica for the benefit of creditors; or (iii)
Genica's applying for or consenting to the appointment of a receiver, trustee or
similar officer for any substantial part of its property; or such receiver,
trustee or similar officer's appointment without the application or consent of
Genica, if such appointment shall continue undischarged for a period of ninety
(90) days; or (iv) Genica's instituting (by petition, application, answer,
consent or otherwise) any bankruptcy, insolvency arrangement, or similar
proceeding relating to Genica under the laws of any jurisdiction; or (v) the
institution of any such proceeding (by petition, application or otherwise)
against Genica, if such proceeding shall remain undismissed for a period of
ninety (90) days or the issuance or levy of any

<PAGE>

                                      -16-

judgment, writ, warrant of attachment or execution or similar process against a
substantial part of the property of Genica, if such judgment, writ, or similar
process shall not be released, vacated or fully bonded within ninety (90) days
after its issue or levy; or (vi) loss of Genica's federal or state licenses
permits or accreditation necessary for operation of Genica as a health care
institution.

         8.6. RMS shall have the right to terminate this Agreement by written
notice to Genica upon any change in the ownership or control of Genica or of its
assets. Termination under this Section shall be effective immediately upon
receipt by Genica of RMS' notice of termination. For such purposes, a "change in
ownership or control" shall mean that [ ]%* of the voting stock of Genica become
subject to the control of a person or entity, or any related group of persons or
entities acting in concert, which person(s) or entity(ies) did not control such
proportion of voting stock as of the effective date of the Agreement.
Analogously, RMS shall have the right to terminate this Agreement upon any
transfer or sale of [ ]%* of the assets of Genica to another party.

         8.7. Breach. Upon any breach of or default of a material term under
this Agreement by Genica, RMS may terminate this Agreement upon thirty (30)
days' written notice to Genica. Said notice shall become effective at the end of
the thirty-day (30) period, unless during said period Genica fully cures such
breach or default and notifies RMS of such a cure.

<PAGE>

                                      -17-

         8.8. Upon termination of this Agreement as provided herein, all
immunities and rights granted to Genica hereunder shall revert to or be retained
by RMS. To the extent RMS has licensed technology or know-how of Genica pursuant
to Article 6 hereto, those licenses shall remain in force according to their
terms.

         8.9. Genica's obligations to report to RMS and to pay royalties to RMS
as to the Licensed Services performed under the Agreement prior to termination
or expiration of the Agreement shall survive such termination or expiration.

9.       Confidentiality-Publicity
         -------------------------

         9.1. Except as otherwise specifically provided in Section 2.6, Genica
agrees to obtain RMS' approval before distributing any written information,
including but not limited to promotional and sales materials, to Third Parties
which contains references to RMS or this Agreement. RMS' approval shall not be
unreasonably withheld or delayed and, in any event, RMS' decision shall be
rendered within three (3) weeks of receipt of the written information. Once
approved, such materials, or abstracts of such materials, which do not
materially alter the context of the material originally approved may be
reprinted during the term of the Agreement without further approval by RMS
unless RMS has notified Genica in writing of its decision to withdraw permission
for such use.

<PAGE>

                                      -18-

         9.2. Each Party agrees that any financial, legal or business
information or any technical information disclosed to it (the "Receiving Party")
by the other (the "Disclosing Party") in connection with this Agreement shall be
considered confidential and proprietary and the Receiving Party shall not
disclose same to any Third Party and shall hold it in confidence for a period of
five (5) years and will not use it other than as permitted under this Agreement
provided, however, that any information, know-how or data which is orally
disclosed to the Receiving Party shall not be considered confidential and
proprietary unless such oral disclosure is reduced to writing and given to the
Receiving Party in written form within thirty (30) days after oral disclosure
thereof. Such confidential and proprietary information shall include, without
limitation, marketing and sales information, commercialization plans and
strategies, research and development work plans, and technical information such
as patent applications, inventions, trade secrets, systems, methods, apparatus,
designs, tangible material, organisms and products and derivatives thereof.

         9.3. The above obligations of confidentiality shall not be applicable
to the extent:

              (a)    such information is general public knowledge or, after
                     disclosure hereunder, becomes general or public knowledge
                     through no fault of the Receiving Party; or

<PAGE>

                                      -19-

              (b)    such information can be shown by the Receiving Party by its
                     written records to have been in its possession prior to
                     receipt thereof hereunder; or

              (c)    such information is received by the Receiving Party from
                     any Third Party for use or disclosure by the Receiving
                     Party without any obligation to the Disclosing Party
                     provided, however, that information received by the
                     Receiving Party from any Third Party funded by the
                     Disclosing Party (e.g. consultants, subcontractors, etc.)
                     shall not be released from confidentiality under this
                     exception; or

              (d)    the disclosure of such information is reasonably needed for
                     use in connection with performing, offering and selling
                     Licensed Services; or

              (e)    the disclosure of such information is required or desirable
                     to comply with or fulfill governmental requirements,
                     submissions to governmental bodies, or the securing of
                     regulatory approvals.

         9.4. With the exception of Section 2.6, each party shall, to the extent
reasonably practicable, maintain the confidentiality of the provisions of this
Agreement and shall refrain from making any public announcement or disclosure of
the terms of this Agreement without the prior consent of the other party, except
to the extent a party concludes in good faith that

<PAGE>

                                      -20-

such disclosure is required under applicable law or regulations, in which case
the other party shall be notified in advance.

10.      Compliance
         ----------

         In exercising any and all rights and in performing its obligations
hereunder, Genica shall comply fully with any and all applicable laws,
regulations and ordinances and shall obtain and keep in effect licenses, permits
and other governmental approvals, whether at the federal, state or local levels,
necessary or appropriate to carry on its activities hereunder. Genica further
agrees to refrain from any activities that would have an adverse effect on the
business reputation of RMS. RMS will advise Genica of any such activities and
Genica will have thirty (30) days to correct such activity.

11.      Assignment
         ----------

         This Agreement shall not be assigned by Genica (including without
limitation any purported assignment or transfer that would arise from a sale or
transfer of Genica's business). RMS may assign all or any part of its rights and
obligations under this Agreement at any time without the consent of Genica.
Genica agrees to execute such further acknowledgments or other instruments as
RMS may reasonably request in connection with such assignment.

12.      Negation of Warranties and Indemnity
         ------------------------------------

         12.1.    Nothing in this Agreement shall be construed as:

<PAGE>

                                      -21-

                 (a)     a warranty or representation by RMS as to the validity
                         or scope of any Licensed Technology;

                 (b)     a warranty or representation that the practice of the
                         Licensed Technology is or will be free from
                         infringement of patents of Third Parties;

                 (c)     an obligation to bring or prosecute actions or suits
                         against Third Parties for infringement;

                 (d)     except as expressly set forth herein, conferring the
                         right to use in advertising, publicity or otherwise any
                         trademark, trade name, or names, or any contraction,
                         abbreviation, simulation or adaptation thereof, of RMS;

                 (e)     conferring by implication, estoppel or otherwise any
                         license, right or immunity under any patents or patent
                         applications of RMS other than those specified in PCR
                         Technology, regardless of whether such patents and
                         patent applications are dominant or subordinate to
                         those in PCR Technology;

                 (f)     an obligation to furnish any know-how not provided in
                         PCR Technology; or

<PAGE>

                                      -22-

                 (g)     creating any agency, partnership, joint venture or
                         similar relationship between RMS and Genica.

         12.2. RMS MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE.

         12.3. Genica acknowledges that the technology licensed hereby is newly
developed, and agrees to take all reasonable precautions to prevent death,
personal injury, illness and property damage from the use of such technology.
Genica shall assume full responsibility for its use of the Licensed Technology
and shall defend, indemnify and hold RMS harmless from and against all
liability, demands, damages, expenses (including attorneys' fees) and losses for
death, personal injury, illness, property damage or any other injury or damage,
including any damages or expenses arising in connection with state or federal
regulatory action (collectively "Damages"), resulting from the use by Genica,
including its officers, directors, agents and employees, of the Licensed
Technology except, and to the extent that such Damages are caused by the
negligence or willful misconduct of RMS.

13.      General
         -------

         13.1. This Agreement constitutes the entire agreement between The
Parties as to the subject matter hereof, and all prior negotiations,
representations, agreements and understandings are merged into, extinguished by
and completely expressed by it. This Agreement may

<PAGE>

                                      -23-

be modified or amended only by a writing executed by authorized officers of each
of The Parties.

         13.2. Any notice required or permitted to be given by this Agreement
shall be given by postpaid, first class, registered or certified mail, or by
courier or facsimile, properly addressed to the other party at the respective
address as shown below:

If to RMS:

                           Roche Molecular Systems, Inc.
                           340 Kingsland Street
                           Nutley, New Jersey 07110
                           Attn:  Corporate Secretary

with a copy to:

                           Roche Molecular Systems, Inc.
                           1145 Atlantic Avenue, Suite 100
                           Alameda, California 94501
                           Attn:  Licensing Manager

If to Genica:

                           Genica Pharmaceuticals Corporation
                           Two Biotech Park
                           377 Plantation Street
                           Worcester, Massachusetts 01605
                           Attn:  Robert E. Flaherty
                                  President

Either party may change its address by providing notice to the other party.
Unless otherwise specified herein, any notice given in accordance with the
foregoing shall be deemed given

<PAGE>

                                      -24-

within four (4) full business days after the day of mailing, or one full day
after the date of delivery to the courier, or the date of facsimile
transmission, as the case will be.

         13.3. Governing Law and Venue. This Agreement and its effect are
               -----------------------
subject to and shall be construed and enforced in accordance with the law of the
State of New Jersey, U.S.A., except as to any issue which by the law of New
Jersey depends upon the validity, scope or enforceability of any patent within
the Licensed Technology, which issue shall be determined in accordance with the
applicable patent laws of the United States. The Parties agree that the
exclusive jurisdiction and venue for any dispute or controversy arising from
this Agreement shall be in the United States District Court for the District of
New Jersey if federal jurisdiction exists, and if no federal jurisdiction
exists, then in the Superior Court of New Jersey.

         13.4. Arbitration. Notwithstanding the provisions of Section 13.3
               -----------
above, any dispute concerning solely the determination of facts such as, but not
limited to, (i) the value of a Combination Service and a Licensed Service
pursuant to Section 1.8; (ii) a determination of royalty rate payments owed
pursuant to Section 4.1; (iii) compliance with quality assurance pursuant to
Article 5; or (iv) good faith compliance with Article 6; and which dispute does
not involve a question of law, shall be settled by final and binding arbitration
at a mutually convenient location in the State of New Jersey pursuant to the
commercial arbitration rules of the American Arbitration Association, in
accordance with the following procedural process:

<PAGE>

                                      -25-

                 (a)       The arbitration tribunal shall consist of three
                           arbitrators. Each party shall nominate in the request
                           for arbitration and the answer thereto one arbitrator
                           and the two arbitrators so named will then jointly
                           appoint the third arbitrator as chairman of the
                           arbitration tribunal.

                 (b)       The decision of the arbitration tribunal shall be
                           final and judgment upon such decision may be entered
                           in any competent court for juridical acceptance of
                           such an award and order of enforcement. Each party
                           hereby submits itself to the jurisdiction of the
                           courts of the place of arbitration, but only for the
                           entry of judgment with respect to the decision of the
                           arbitrators hereunder.

         13.5. Nothing in this Agreement shall be construed so as to require the
commission of any act contrary to law, and wherever there is any conflict
between any provision of this Agreement or concerning the legal right of The
Parties to enter into this contract and any statute, law, ordinance or treaty,
the latter shall prevail, but in such event the affected provisions of the
Agreement shall be curtailed and limited only to the extent necessary to bring
it within the applicable legal requirements.

         13.6. If any provision of this Agreement is held to be unenforceable
for any reason, it shall be adjusted rather than voided, if possible, in order
to achieve the intent of the parties to

<PAGE>

                                      -26-

the extent possible. In any event, all other provisions of this Agreement shall
be deemed valid and enforceable to the full extent possible.

         IN WITNESS WHEREOF, The Parties hereto have set their hands and seals
and duly executed this Agreement on the date(s) indicated below, to be effective
on Effective Date as defined herein.

ROCHE MOLECULAR SYSTEMS, INC.                       GENICA PHARMACEUTICALS
                                                    CORPORATION

By:  /s/ Kathy Ordonez                              By: /s/ Robert E. Flaherty
     --------------------------------------             ------------------------

Name:  Kathy Ordonez                                Name:  Robert E. Flaherty

Title:  President                                   Title:  President

Date:  6/14/94                                      Date:  6/22/94
       ------------------------------------                ---------------------

<PAGE>

                                Exhibit 10.1(j)

                                  ATTACHMENT I
                                  ------------

                              COMBINATION SERVICES
                              --------------------

                                                  Percent of Net Service
                                                  Revenues for Combination
                                                  Services which is Attributable
Licensed Services                                 to Licensed Services
-----------------
Apo E                                             [   ]%*

Fragile X                                         [   ]%*

Amyloidosis                                       [   ]%*

CSA-1 (Spinocerebellar Ataxia Type I)             [   ]%*

Muscular Dystrophy                                $[       ]*

<PAGE>

                                      -28-

November 30, 1999

Michael A. Boss, Ph.D.
Vice President, Research and Development
ATHENA DIAGNOSTICS, INC.
Four Biotech Park - 377 Plantation Street
Worcester, MA  01605

Re:    Agreement Effective June 22, 1994 between Roche Molecular Systems, Inc.
       ("RMS") and Athena Diagnostics, Inc. ("ADI") for use of the Polymerase
       Chain Reaction (PCR) Technology in Human Diagnostic Services ("the
       Agreement")

Dear Dr. Boss:

Pursuant to RMS's review of the descriptions provided with Dr. Palatucci's
letter of November 11, 1999 on the following two tests offered by Athena, the
tests are approved as a Combination Services with royalty-bearing fractions of [
]%*. This royalty-bearing fraction is in recognition of the component of genetic
counseling as a part of the billed price.

                 Combination Service                     Royalty Bearing %

Spinocerebellar ataxia Type 12 (SCA 12)                         [ ]*
Dentatorubro-pallidoluysian atrophy (DRPLA)                     [ ]*
Charcot-Marie-Tooth disease (EGR 2)                             [ ]*
Charcot-Marie-Tooth disease (PMP 22)                            [ ]*
Cerebral autosomal dominant arteriopathy,
  sub-cortical infarcts and leukoencephalopathy (CADASIL)       [ ]*

Enclosed is a revised Attachment I to the referenced Agreement effective January
1, 2000 including these tests as Combination Services and which supersedes the
previous Attachments I. Please acknowledge ADI's acceptance of the new
Attachment I by having an authorized representative of ADI execute both copies
of this letter, each of which, once executed, shall con-

<PAGE>

                                      -29-

stitute an original. Please forward one of the executed duplicate originals to
the attention of Donna Donohue, Licensing Specialist, at the above address and
retain the other.

Regards,                                       Agreed and Accepted
ROCHE MOLECULAR SYSTEMS, INC.                  ATHENA DIAGNOSTICS, INC.

/s/ Thomas White                               By: /s/  Robert Flaherty
                                                   -----------------------------
                                                    (authorized signature)

Thomas White, Ph.D.                            Name:  Robert Flaherty
                                                    ----------------------------

Vice President, R&D                            Title: President
                                                    ----------------------------

Enclosure                                      Date:  12/21/99
                                                    ----------------------------

Apprv'd as To Form
LAW DEPT
By:  /s/
     ------------------------

<PAGE>

ATTACHMENT I

                              COMBINATION SERVICES
                              --------------------

<TABLE>
<CAPTION>
                                                                       Percent of Net Service
                                                                       Revenues for Combination
                                                                       Services which is Attributable
Licensed Services                                                      to Licensed Services
-----------------                                                      --------------------
<S>                                                                    <C>
Amyloidosis                                                                          [ ]*
Apo E                                                                                [ ]*
Cerebral autosomal dominant arteriopathy, sub-cortical infarcts and
  leukoencephalopathy (CADASIL)                                                      [ ]*
Charcot-Marie-Tooth Disease (EGR 2)                                                  [ ]*
Charcot-Marie-Tooth Disease (PMP 22)                                                 [ ]*
CMT1B                                                                                [ ]*
CMTX (not CMT1A)                                                                     [ ]*
Dentatorubro-pallidoluysian atrophy (DRPLA)                                          [ ]*
Dystonia                                                                             [ ]*
Factor V Leiden                                                                      [ ]*
Fragile X                                                                            [ ]*
Friedrech's Ataxia                                                                   [ ]*
Huntington's Disease                                                                 [ ]*
Kennedy's Disease                                                                    [ ]*
Machado-Joseph Disease                                                               [ ]*
Mitochondrial DNA (not KSS/CPEO)                                                     [ ]*
Muscular Dystrophy                                                                  $[    ]
Myotonic Dystrophy                                                                   [ ]*
Oculopharyngeal Muscular Dystrophy                                                   [ ]*
Presenilin 1                                                                         [ ]*
Spinal Muscular Atrophy                                                              [ ]*
Spinocerebellar Ataxia Type 1 (SCA 1)                                                [ ]*
Spinocerebellar Ataxia Type 2 (SCA 2)                                                [ ]*
Spinocerebellar Ataxia Type 6 (SCA 6)                                                [ ]*
Spinocerebellar Ataxia Type 7 (SCA 7)                                                [ ]*
Spinocerebellar Ataxia Type 8 (SCA 8)                                                [ ]*
Spinocerebellar Ataxia Type 12 (SCA 12)                                              [ ]*
</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}]]